additional treatments. Demographic and Clinical Characteristics Using data from the SEER registry, we determined age, sex, race, Hispanic ethnicity, marital status, area income, cancer stage, and disease subsite. 13 Dual Medicaid insurance and Charlson
Search Results
Jeremy P. Harris, Mehr Kashyap, Jessi N. Humphreys, Daniel T. Chang, and Erqi L. Pollom
Nina N. Sanford, David J. Sher, Xiaohan Xu, Chul Ahn, Anthony V. D’Amico, Ayal A. Aizer, and Brandon A. Mahal
Southwestern Medical Center deemed the study exempt given the use of public deidentified data. Statistical Analysis Baseline Characteristics Baseline characteristics, including demographic and socioeconomic variables, were reported for the entire cohort (N=34
Carlos J. Roldan, Matthew Chung, Lei Feng, and Eduardo Bruera
.4 (SAS Institute Inc.) and Splus 8.2 (TIBCO Software Inc) were used for all analyses. Results Patient Characteristics We identified 350 adult patients who were prescribed MB oral rinse for oral pain from mucositis related to cancer therapy
Willemieke P.M. Dijksterhuis, Anouk E.J. Latenstein, Jessy Joy van Kleef, Rob H.A. Verhoeven, Jeanne H.M. de Vries, Marije Slingerland, Elles Steenhagen, Joos Heisterkamp, Liesbeth M. Timmermans, Marian A.E. de van der Schueren, Martijn G.H. van Oijen, Sandra Beijer, and Hanneke W.M. van Laarhoven
is provided by the patient. 27 Data on patient and tumor characteristics, treatment, and survival were extracted from the Netherlands Cancer Registry (NCR), which is a population-based registry that covers the total Dutch population of >17 million
Yue Chen, Zi-Qi Zheng, Fo-Ping Chen, Jian-Ye Yan, Xiao-Dan Huang, Feng Li, Ying Sun, and Guan-Qun Zhou
the role of PORT in survival outcome, which would help surgeons and radiologists provide individualized recommendations regarding PORT to patients with ACC. Patients and Methods Patient Characteristics From January 2000 through December 2017, 480
Vinayak Muralidhar, Paul L. Nguyen, Brandon A. Mahal, David D. Yang, Kent W. Mouw, Brent S. Rose, Clair J. Beard, Jason A. Efstathiou, Neil E. Martin, Martin T. King, and Peter F. Orio III
PSA levels ≥98.0 ng/mL are grouped together without further granularity regarding the exact PSA level. Median age and follow-up were compared using the Kruskal-Wallis test; other baseline patient characteristics were compared using the chi-square test
Matthew G. Fury, Eric Sherman, Donna Lisa, Neeraj Agarwal, Kenneth Algazy, Bruce Brockstein, Corey Langer, Dean Lim, Ranee Mehra, Sandeep K. Rajan, Susan Korte, Brynna Lipson, Furhan Yunus, Tawee Tanvetyanon, Stephanie Smith-Marrone, Kenneth Ng, Han Xiao, Sofia Haque, and David G. Pfister
more of the first 18 patients (each group treated separately) experienced a dose-limiting toxicity (as defined in the protocol) during cycle 1 or 2, that group would be closed because of excess toxicity. Results Patient Characteristics The
Min Huang, Joyce O’Shaughnessy, Jing Zhao, Amin Haiderali, Javier Cortes, Scott Ramsey, Andrew Briggs, Vassiliki Karantza, Gursel Aktan, Cynthia Z. Qi, Chenyang Gu, Jipan Xie, Muhan Yuan, John Cook, Michael Untch, Peter Schmid, and Peter A. Fasching
4 RCTs, carboplatin in 3 RCTs, and nab-paclitaxel, everolimus, and anthracycline in 1 RCT each. Different pCR definitions were used across trials, of which ypT0/is ypN0 was the most common. The characteristics of the included trials are listed in
Amy A. Kirkham, Karen A. Gelmon, Cheri L. Van Patten, Kelcey A. Bland, Holly Wollmann, Donald C. McKenzie, Taryne Landry, and Kristin L. Campbell
Baseline characteristics were compared between groups using independent t tests and chi-square tests. Relative risk (RR; with 95% confidence intervals and number needed to treat [NNT]) was used to compare categorical metrics of treatment tolerance
Lucas K. Vitzthum, Chris Straka, Reith R. Sarkar, Rana McKay, J. Michael Randall, Ajay Sandhu, James D. Murphy, and Brent S. Rose
year before PCa diagnosis as previously described. 15 , 16 Table 1. Patient and Tumor Characteristics Information on treatment with ADT was obtained from the VA pharmacy database. CAB was defined as treatment with a nonsteroidal androgen receptor
